BioPharmSignal logoBioPharmSignal

Biotech News

Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

Azenta Life Sciences (AZTA)Azenta Life Sciences2026-06-25 13:46 ESTEarnings

AZTA (AZTA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is azta.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

AZTAAzenta Life Sciences2026-06-25 13:46 EST

Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report

AZTAAzenta Life Sciences2026-06-25 13:46 EST

Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference

AZTAAzenta Life Sciences2026-06-25 13:46 EST

Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

AZTAAzenta Life Sciences2026-06-25 13:46 EST

Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

AZTAAzenta Life Sciences2026-06-25 13:46 EST

Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

View all latest news

Azenta Life Sciences

Azenta Life Sciences is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

AZTAAzenta Life Sciences2026-06-26 08:52 EST

Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report

AZTAAzenta Life Sciences2026-06-26 08:52 EST

Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference

AZTAAzenta Life Sciences2026-06-26 08:52 EST

Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

AZTAAzenta Life Sciences2026-06-26 08:52 EST

Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

AZTAAzenta Life Sciences2026-06-26 08:52 EST

Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States